Skip to main content
Premium Trial:

Request an Annual Quote

Arrowhead Files to Begin Phase I Trial of HBV Drug

Premium

Arrowhead Research said this week that it has filed an application with Australian regulators to begin phase I testing of its hepatitis B treatment ARC-520.

Arrowhead acquired the drug through its 2011 purchase of Roche’s RNA therapeutics assets (GSN 11/27/2011). It comprises cholesterol-conjugated siRNAs against HBV and a proprietary delivery technology called dynamic polyconjugates.

Earlier this year, Arrowhead’s president and CEO said that the company plans to run two phase I studies for ARC-520 — one in healthy patients in Australia and a second, to begin before the end of 2013, in HBV-infected patients in Hong Kong.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.